Meeting
2018 ASCO Annual Meeting
An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Authors
Jiayu Wang
Department of Medical Oncology, National Caner Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Jiayu Wang , Binghe Xu , Wenxiang Wang , Jianmin Fang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT02881138
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1030)
DOI
10.1200/JCO.2018.36.15_suppl.1030
Abstract #
1030
Poster Bd #
111
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Pyrotinib plus nab-paclitaxel in patients with HER2-positive advanced or metastatic breast cancer: A multicenter, single-arm, open-label phase 2 trial.
First Author: Huan Li
Poster
2017 ASCO Annual Meeting
Proof-of concept phase I study of everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic breast cancer or other solid tumors: Evaluating synergy and overcoming resistance.
First Author: Shubham Pant
Poster
2018 ASCO Annual Meeting
An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer.
First Author: Binghe Xu
Poster
2018 ASCO Annual Meeting
A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.
First Author: Krystal Pauline Cascetta